A Study of LAD106 in Healthy Adult Participants

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.

Key facts

Study ID
NCT07471932
Run by
Almirall, S.A.
People needed
93
Starts
2026-02-17
Expected to finish
2027-05-31
Last updated by the study team
2026-05-15

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.